Literature DB >> 8015071

Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis.

D Felsen1, S Frye, L A Trimble, T G Bavendam, C L Parsons, Y Sim, E D Vaughan.   

Abstract

Interstitial cystitis is a syndrome of urinary urgency, frequency and suprapubic pain. We investigated the role of inflammatory mediators in 96 patients with histories and symptoms consistent with interstitial cystitis, and 13 controls from The New York Hospital-Cornell Medical Center, University of Washington and University of California at San Diego. Patients were classified into either group A (meets all criteria of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases for inclusion in research studies), group B (meets all of these criteria but without glomerulations) or an "other" group. A small number of group A patients had detectable interleukin-6 in the urine. Urinary concentrations of tumor necrosis factor, prostaglandins E2, D2 and F2 alpha, and thromboxane B2 were not different among either patient groups or controls. Urine specimens contained inhibitors of the bioactivity of interleukin-6 and tumor necrosis factors but no differences between patients or controls were found. No factors chemotactic for human neutrophils were detected in a small patient sample. Bladder wash fluid concentrations of prostaglandins E2, D2 and F2 alpha, and thromboxane were much lower than urinary levels. Bladder wash fluid interleukin-6 and tumor necrosis factor were not detectable. The results suggest that while a small subset of patients may have elevated levels of interleukin-6 the majority of patients do not appear to have elevated levels of inflammatory mediators in the urine or bladder wash fluid. Evaluation of patient bladder tissue may indicate changes not detectable in urine or bladder wash fluid. Alternatively, other etiologies must be considered in those patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8015071     DOI: 10.1016/s0022-5347(17)32739-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo.

Authors:  Wei Yang; Yongsoo Kim; Taek-Kyun Kim; Susan K Keay; Kwang Pyo Kim; Hanno Steen; Michael R Freeman; Daehee Hwang; Jayoung Kim
Journal:  BJU Int       Date:  2012-06-28       Impact factor: 5.588

Review 2.  Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.

Authors:  Ioannis Mykoniatis; Stavros Tsiakaras; Michael Samarinas; Anastasios Anastasiadis; Evangelos N Symeonidis; Petros Sountoulides
Journal:  Biologics       Date:  2022-05-20

3.  Is there a relation between urinary interleukin-6 levels and symptoms before and after intra-vesical glycosaminoglycan substitution therapy in patients with bladder pain syndrome/interstitial cystitis?

Authors:  Lukas K Daha; Dara Lazar; Reiner Simak; Heinz Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-03-20

Review 4.  Treatment approaches for painful bladder syndrome/interstitial cystitis.

Authors:  Theoharis C Theoharides
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link.

Authors:  Rajiv Saini; Ricardo R Gonzalez; Alexis E Te
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 6.  Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.

Authors:  Hung-Yu Lin; Jian-He Lu; Shu-Mien Chuang; Kuang-Shun Chueh; Tai-Jui Juan; Yi-Chang Liu; Yung-Shun Juan
Journal:  Diagnostics (Basel)       Date:  2021-12-29

Review 7.  Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives.

Authors:  Yoshiyuki Akiyama
Journal:  Diagnostics (Basel)       Date:  2021-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.